Form 4: Skye Bioscience Director Annalisa Jenkins Granted Stock Options

Director Annalisa Jenkins acquired stock options in Skye Bioscience, Inc. on October 28, 2024.

Summary

• Annalisa Jenkins, a director of Skye Bioscience, Inc., was granted stock options on October 28, 2024.
• The stock options allow Jenkins to purchase 70,000 shares of Skye Bioscience common stock at an exercise price of $5.15 per share.
• The options vest in equal monthly installments over one year, starting October 28, 2024, and expire on October 27, 2034.
• Following the transaction, Jenkins directly owns 70,000 derivative securities.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing related to stock option grants, which is neither particularly positive nor negative. It's a routine part of corporate governance.

Positives

• The granting of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule incentivizes the director to remain with the company for at least one year.

Industry Context

Stock options are a common form of compensation for directors and executives in publicly traded companies, particularly in the biotech industry, to align their interests with those of shareholders and incentivize long-term value creation.

Comparison to Industry Standards

• Stock option grants to directors are a standard practice in publicly traded companies, especially in the biotech sector.
• The vesting schedule of one year is fairly typical, although some companies may use longer vesting periods.
• The exercise price is set at $5.15, which may be at or above the current market price of the stock at the time of the grant.

Stakeholder Impact

• The stock option grant could potentially dilute existing shareholders if the options are exercised.
• The grant incentivizes the director to work towards increasing shareholder value.

Key Dates